Monitoring of cellular resistance to cancer chemotherapy

Awtar Krishan; Poonam Arya

doi:10.1016/S0889-8588(01)00016-8

Monitoring of cellular resistance to cancer chemotherapy

Awtar Krishan, Poonam Arya

Pathology

Research output: Contribution to journal › Review article

10 Scopus citations

Abstract

Cellular resistance to a broad spectrum of natural products used as antitumor drugs is believed to be a major cause for the failure of chemotherapy. Flow cytometry has been used for monitoring the expression of drug resistance markers, determining accumulation of fluorescent drugs, and for screening of drugs that enhance chemosensitivity by blocking efflux and enhancing drug retention. This article reviews recent developments in our understanding of the multiple drug resistance phenotype and the use of flow cytometry for the study of drug efflux and its modulation in human tumor cells.

Original language	English (US)
Pages (from-to)	357-372
Number of pages	16
Journal	Hematology/Oncology Clinics of North America
Volume	16
Issue number	2
DOIs	https://doi.org/10.1016/S0889-8588(01)00016-8
State	Published - Jan 1 2002

Fingerprint

ASJC Scopus subject areas

Hematology
Oncology

Cite this

Krishan, A., & Arya, P. (2002). Monitoring of cellular resistance to cancer chemotherapy. Hematology/Oncology Clinics of North America, 16(2), 357-372. https://doi.org/10.1016/S0889-8588(01)00016-8

@article{2aaf0779cf4d4f618cd4f4c5e86aa793,

title = "Monitoring of cellular resistance to cancer chemotherapy",

abstract = "Cellular resistance to a broad spectrum of natural products used as antitumor drugs is believed to be a major cause for the failure of chemotherapy. Flow cytometry has been used for monitoring the expression of drug resistance markers, determining accumulation of fluorescent drugs, and for screening of drugs that enhance chemosensitivity by blocking efflux and enhancing drug retention. This article reviews recent developments in our understanding of the multiple drug resistance phenotype and the use of flow cytometry for the study of drug efflux and its modulation in human tumor cells.",

author = "Awtar Krishan and Poonam Arya",

year = "2002",

month = jan

day = "1",

doi = "10.1016/S0889-8588(01)00016-8",

language = "English (US)",

volume = "16",

pages = "357--372",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Monitoring of cellular resistance to cancer chemotherapy

AU - Krishan, Awtar

AU - Arya, Poonam

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Cellular resistance to a broad spectrum of natural products used as antitumor drugs is believed to be a major cause for the failure of chemotherapy. Flow cytometry has been used for monitoring the expression of drug resistance markers, determining accumulation of fluorescent drugs, and for screening of drugs that enhance chemosensitivity by blocking efflux and enhancing drug retention. This article reviews recent developments in our understanding of the multiple drug resistance phenotype and the use of flow cytometry for the study of drug efflux and its modulation in human tumor cells.

AB - Cellular resistance to a broad spectrum of natural products used as antitumor drugs is believed to be a major cause for the failure of chemotherapy. Flow cytometry has been used for monitoring the expression of drug resistance markers, determining accumulation of fluorescent drugs, and for screening of drugs that enhance chemosensitivity by blocking efflux and enhancing drug retention. This article reviews recent developments in our understanding of the multiple drug resistance phenotype and the use of flow cytometry for the study of drug efflux and its modulation in human tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=0036080406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036080406&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(01)00016-8

DO - 10.1016/S0889-8588(01)00016-8

M3 - Review article

C2 - 12094476

AN - SCOPUS:0036080406

VL - 16

SP - 357

EP - 372

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -

Access to Document

10.1016/S0889-8588(01)00016-8